- $3.25bn
- $2.94bn
- $460.16m
HK-listed Zai Lab rises on narrower loss in Q3
Brief: Zai Lab Announces Breakthrough Therapy Designation Granted For Repotrectinib
Brief: Zai Lab Ltd Says HY Net Loss $170.0 Mln
Brief: Zai Lab Says Looking Ahead, Have Potential For Significant Revenue Growth Over Next 5 Years
Brief: Zai Lab Announces First Patient Treated In Mainland China For Study Of Bemarituzumab
Announces Acceptance By China's Nmpa Of BLA For Efgartigimod Alfa Injection For Patients With Generalized Myasthenia Gravis
Brief: Zai Lab Announces Promotion Of Yajing Chen To Chief Financial Officer
Brief: Zai Lab Says National Medical Products Administration Approved Biologics License Application For Vyvgart
China's NMPA approves Argenx's and Zai Lab's BLA for muscle-weakening disease treatment (updated)
China's NMPA approves Argenx's and Zai Lab's BLA for muscle-weakening disease treatment
Zai Lab, Argenx rise as muscle-weakening disease drug gets approval in China
Brief: Zai Lab And Argenx Announce Approval Of Vyvgart® (Efgartigimod Alfa Injection) For Generalized Myasthenia Gravis In China
Brief: Zai Lab Announces NDA Acceptance Of Repotrectinib By China's NMPA
Zai Lab down as lung cancer device study raises concerns over commercial use
Brief: Zai Lab And Novocure Announce Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant And Clinically Meaningful Extension In Overall Survival For Patients With Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Zai Lab rises on promising early data from cancer drug trial
Zai Lab rises on promising early data from cancer drug trial
Brief: Zai Lab To Highlight New Data From Its Oncology Pipeline
Brief: Zai Lab Announces That Repotrectinib Granted Priority Review By China’S NMPA